发布求助
文献互助 智能选刊 最新文献

Nature biotechnology最新文献

筛选
英文 中文
Engineered E. coli creates biodegradable plastics
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02653-5
Iris Marchal
{"title":"Engineered E. coli creates biodegradable plastics","authors":"Iris Marchal","doi":"10.1038/s41587-025-02653-5","DOIUrl":"https://doi.org/10.1038/s41587-025-02653-5","url":null,"abstract":"<p>Replacing fossil-fuel-based plastics with bio-based polymers is crucial in tackling the environmental issues caused by our heavy reliance on these materials. Microorganisms can synthesize numerous biopolymers but have not yet been reported to produce one of the most promising polymers, known as polyester amides (PEAs). In a study published in <i>Nature Chemical Biology</i>, Chae et al. engineer a new-to-nature metabolic pathway in <i>Escherichia coli</i> to biosynthesize PEAs, which might one day be used in various industrial applications.</p><p>The production of PEAs in <i>E. coli</i> was accomplished through a two-step synthetic pathway. First, the authors selected the broad-activity β-alanine coenzyme A (CoA) transferase from <i>Clostridium propionicum</i> to activate amino acids to amino acyl-CoA. This step was followed by polymerization of amino acyl-CoA by a mutant PHA synthase from <i>Pseudomonas</i> species, which accepts various monomers as substrates. Metabolic flux optimization resulted in the biosynthesis of two PEAs from glucose as the sole carbon source. Further engineering and optimization of the culture medium was performed to enhance production titers and amino acid fractions. The engineered bacteria converted more than 50% of dry cell weight into polymers.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"122 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Roche strikes $5.3 billion amylin deal 罗氏斥资 53 亿美元收购氨甲蝶呤
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02657-1
{"title":"Roche strikes $5.3 billion amylin deal","authors":"","doi":"10.1038/s41587-025-02657-1","DOIUrl":"https://doi.org/10.1038/s41587-025-02657-1","url":null,"abstract":"<p>Roche is gaining access to petrelintide, a potentially best-in-class amylin analog, paying Copenhagen-based Zealand Pharma $1.65 billion up front and up to $5.3 billion in total to co-develop the weight-loss molecule. Petrelintide is a long-acting acylated version of the pancreatic peptide amylin. Several companies are pursuing amylin analogs as antiobesity agents because they work by increasing satiety. Their advantage over glucagon-like peptide-1 (GLP-1) agonists such as Wegovy (semaglutide) is that they cause less nausea and vomiting, and may lead to less muscle loss, according to rodent studies. Amylin analogs mimic the natural pancreatic peptide amylin, which is secreted with insulin by the pancreas, whereas GLP-1 agonists mimic incretin hormones, produced in the gut to suppress appetite.</p><p>So far, in an ongoing phase 2 trial, participants receiving petrelintide, given by once-weekly injection, lost only 7% more weight than people receiving placebo. A 15–20% weight loss, similar to that of GLP-1 agonists, is the aim for future trials.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"16 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A shifting market environment and strategies fueling innovation in prostate cancer treatment 不断变化的市场环境和推动前列腺癌治疗创新的战略
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02617-9
Michael Casasanta, Nicholas Frame, Oded Ben-Joseph
{"title":"A shifting market environment and strategies fueling innovation in prostate cancer treatment","authors":"Michael Casasanta, Nicholas Frame, Oded Ben-Joseph","doi":"10.1038/s41587-025-02617-9","DOIUrl":"https://doi.org/10.1038/s41587-025-02617-9","url":null,"abstract":"Blockbuster drug patent expiration, advances in enabling technology, and the emergence of personalized medicine for prostate cancer treatment create a landscape worth examining.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"108 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Making cell therapy accessible: challenges and opportunities
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02625-9
Iris Marchal
{"title":"Making cell therapy accessible: challenges and opportunities","authors":"Iris Marchal","doi":"10.1038/s41587-025-02625-9","DOIUrl":"https://doi.org/10.1038/s41587-025-02625-9","url":null,"abstract":"Despite major advances in bringing cancer cell therapies to the clinic, their widespread accessibility remains a substantial challenge. High manufacturing costs, lack of funding and varying regulatory standards have restricted patient access. As the field advances, researchers, clinicians, regulatory bodies, funding agencies and industry will need to work together to overcome these barriers. A group of experts share their insights into the most pressing challenges and promising strategies to make cell therapies more broadly accessible.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"6 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer vaccines: the experts speak 癌症疫苗：专家发言
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02606-y
Iris Marchal
{"title":"Cancer vaccines: the experts speak","authors":"Iris Marchal","doi":"10.1038/s41587-025-02606-y","DOIUrl":"https://doi.org/10.1038/s41587-025-02606-y","url":null,"abstract":"The development of therapeutic cancer vaccines has long been a promising yet challenging field of research. While early efforts were impeded by limited efficacy and immune escape, recent advances in immunotherapy, mRNA technology and tumor antigen discovery have sparked renewed interest in cancer vaccine development. What is the current state of the field, and how should we address the remaining challenges to bring therapeutic cancer vaccines to the clinic? Which modalities hold potential, and what might the future of therapeutic cancer vaccines look like?","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"113 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biotech news from around the world 全球生物技术新闻
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02643-7
{"title":"Biotech news from around the world","authors":"","doi":"10.1038/s41587-025-02643-7","DOIUrl":"https://doi.org/10.1038/s41587-025-02643-7","url":null,"abstract":"<p>Amgen invests $200 million in a new technology center in southern India and plans to invest further in the future to strengthen its operations and R&amp;D capabilities. The site in Hyderabad currently employs 300 people, with plans for 1,700 more recruits skilled in data analytics, AI and digital health technologies.</p><p>The Canadian government cancels a deal with US-based Novavax to buy millions of doses of a COVID-19 vaccine that was to be made in a new biologics manufacturing facility in Montreal. It would have been the first to be produced in Canada. Novavax says the cause is the company not receiving regulatory approval by the end of 2024 for its COVID-19 vaccine using bulk antigen produced at the facility.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"61 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering mitochondrial DNA deletions in human cells improves disease modeling 人体细胞线粒体 DNA 基因缺失工程改善了疾病建模
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02652-6
Iris Marchal
{"title":"Engineering mitochondrial DNA deletions in human cells improves disease modeling","authors":"Iris Marchal","doi":"10.1038/s41587-025-02652-6","DOIUrl":"https://doi.org/10.1038/s41587-025-02652-6","url":null,"abstract":"<p>Genetically modifying human mitochondrial DNA (mtDNA) is challenging when generating large-scale deletions — a common cause of mitochondrial diseases — owing to the absence of double strand break repair machinery in mitochondria. Writing in <i>Cell</i>, Fu et al. describe a method to modulate large mtDNA deletions in human cells by co-expressing end-joining machinery from <i>Mycobacterium</i> or T4 bacteriophage with targeted endonucleases, providing insights into the underlying mechanisms of mitochondrial disease.</p><p>The presence of both normal and mutated mtDNA within cells, known as heteroplasmy, is decisive in mitochondrial disease as the proportion of mutated mtDNA dictates the severity of disease manifestation. To model mtDNA deletions at defined heteroplasmy levels, the authors co-expressed end-joining machinery with the restriction enzyme Scal in epithelial cells, resulting in a panel of cells with mtDNA deletions of around 3.5 kilobases. In-depth characterization of these cells revealed a critical threshold of about 75% heteroplasmy, beyond which cells showed impaired oxidative phosphorylation and reduced cell growth with a loss of TCA cycle metabolites and aspartate levels. Single-cell sequencing detected two nuclear gene expression programs that were deregulated with increased heteroplasmy, revealing a threshold-triggered response and a gradual heteroplasmy-sensing network. The functional relevance of such gene network disruptions should be studied further.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"6 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineering innate immune cells for cancer immunotherapy 先天免疫细胞工程用于癌症免疫疗法
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02629-5
Mubin Tarannum, Xizhong Ding, Marta Barisa, Sabrina Hu, John Anderson, Rizwan Romee, Jin Zhang
{"title":"Engineering innate immune cells for cancer immunotherapy","authors":"Mubin Tarannum, Xizhong Ding, Marta Barisa, Sabrina Hu, John Anderson, Rizwan Romee, Jin Zhang","doi":"10.1038/s41587-025-02629-5","DOIUrl":"https://doi.org/10.1038/s41587-025-02629-5","url":null,"abstract":"<p>Innate immune cells, including natural killer cells, macrophages and γδ T cells, are gaining prominence as promising candidates for cancer immunotherapy. Unlike conventional T cells, these cells possess attributes such as inherent antitumor activity, rapid immune responses, favorable safety profiles and the ability to target diverse malignancies without requiring prior antigen sensitization. In this Review, we examine the engineering strategies used to enhance their anticancer potential. We discuss challenges associated with each cell type and summarize insights from preclinical and clinical work. We propose strategies to address existing barriers, providing a perspective on the advancement of innate immune engineering as a powerful modality in anticancer treatment.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"30 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the patent landscape of TROP2-targeted biologics through deep learning
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02626-8
Yu Xiang, Yuyang Jin, Kunmeng Liu, Benzheng Wei
{"title":"Mapping the patent landscape of TROP2-targeted biologics through deep learning","authors":"Yu Xiang, Yuyang Jin, Kunmeng Liu, Benzheng Wei","doi":"10.1038/s41587-025-02626-8","DOIUrl":"https://doi.org/10.1038/s41587-025-02626-8","url":null,"abstract":"There has been a rapid growth in patents related to TROP2, a transmembrane glycoprotein involved in calcium signal transduction and an attractive target for cancer therapy.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"60 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Putting cancer immunotherapy into spatial context in the clinic 将癌症免疫疗法与临床空间环境相结合
IF 46.9 1区 生物学
Nature biotechnology Pub Date : 2025-04-14 DOI: 10.1038/s41587-025-02596-x
Camilla Engblom, Joakim Lundeberg
{"title":"Putting cancer immunotherapy into spatial context in the clinic","authors":"Camilla Engblom, Joakim Lundeberg","doi":"10.1038/s41587-025-02596-x","DOIUrl":"https://doi.org/10.1038/s41587-025-02596-x","url":null,"abstract":"Spatial omics technologies offer insights into the organization of cellular and molecular components and their interactions within the tumor ecosystem. Overcoming the key challenges to integrating these advances into routine clinical practice will help unlock new treatment options for patients receiving cancer immunotherapy.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"1 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信